#United States #StaySure #Fecal Incontinence #Stewartville #Minnesota Medical

Minnesota Medical Technologies: Pioneering Fecal Incontinence Solutions

Minnesota Medical Technologies Corporation is making headlines as it secures $20.6 million through a Series A funding round led by HM Venture Partners and Southeast Minnesota Capital Partners. This significant investment is poised to accelerate the company’s growth in developing innovative continence care solutions, particularly focusing on its flagship product, StaySure™.

What is StaySure™?

StaySure™ is a unique, single-use device designed to help manage fecal incontinence, a condition that affects more than 2% of global citizens, often leaving them relying on traditional absorbent products like adult diapers. This product aims to provide a discreet, effective alternative that enhances quality of life for its users.

The CEO of Minnesota Medical Technologies, David A. Jonas, expressed excitement regarding the funding, stating that this influx of capital will enable the company to establish a strong operational framework necessary for the U.S. market, especially given that StaySure™ received FDA clearance in July 2025 after extensive clinical trials at Mayo Clinic.

Impact of Funding

The allocated funds will focus on three main areas:
1. Market Entry: Developing a robust commercial and distribution framework to successfully launch StaySure™ across multiple platforms in the U.S.
2. Talent Acquisition: Building a dynamic team in sales, marketing, and customer service to accelerate market penetration, boost brand awareness, and maintain sustainable revenue growth.
3. Financial Stability: Enhancing the company’s financial health through debt reduction that promotes disciplined growth.

With fecal incontinence affecting tens of millions of individuals worldwide, the introduction of StaySure™ can significantly alter the landscape, offering a clinically validated solution to a largely underserved market. Traditional products have dominated the industry for years, but Minnesota Medical Technologies aims to shift this trend by providing innovative care solutions.

A Collaborative Effort

Founded in 2015, the company was established specifically to address this challenging health issue with the expertise of gastroenterologist Dr. Adil Bharucha from Mayo Clinic. The collaboration with such a reputable institution underlines the credibility and potential impact of StaySure™ in the healthcare sector.

Industry Perspective

The healthcare landscape is evolving, and innovative products like StaySure™ represent a critical pivot towards addressing often-neglected conditions. The significant number of individuals currently managing fecal incontinence speaks volumes about the potential market for effective, restorative products. This funding round places Minnesota Medical Technologies in a prime position to exploit this untapped market.

The Road Ahead

Looking forward, the company plans to not just educate physicians about StaySure™ but also involve patients in understanding the benefits of their treatment options. The funding will facilitate increased visibility and accessibility, thus igniting a broader acceptance among both healthcare providers and patients.

As Minnesota Medical Technologies gears up to make StaySure™ available, the industry watches closely, especially given the company's track record stemming from its leadership team, which includes veterans from Rochester Medical Corporation. Their experience and historical success affirm the company’s capability to establish a strong market foothold.

Conclusion

Minnesota Medical Technologies Corporation is on the brink of a transformative journey in continence care solutions with the backing of substantial funding. As StaySure™ makes its way into the U.S. market, the implications for effective management of fecal incontinence could be profound, improving lives and setting a benchmark for future innovations in the healthcare field.